newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022

AUSTIN, Texas, Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its pa